Synapse Alterations in MSA Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- [18F]SynVesT-1 PET as an imaging biomarker for MSA
研究概览
简要总结
Synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (MSA) remains limited.
The aim of this study was to examine spatial synaptic density alterations in MSA patients and evaluate the potential of [18F]SynVesT-1 PET as an imaging biomarker for MSA in both diagnosis and monitoring disease severity.
详细描述
60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent [18F]SynVesT-1 PET/CT for synaptic density assessment. Visual, voxel, and volumetric region-of-interest (VOI) analyses were employed to elucidate synaptic density patterns in the MSA brain and establish visual diagnostic criteria. VOI-based computer-assisted analyses were utilized to develop diagnostic models for MSA.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The MSA patient were diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists.
排除标准
- •encompassed MRI contraindications, a history of epilepsy, stroke, or brain surgery, intracranial organic lesions unrelated to MSA, usage of levetiracetam or brivaracetam, and a history of alcohol or drug abuse
结局指标
主要结局
[18F]SynVesT-1 PET as an imaging biomarker for MSA
时间窗: 10 months
evaluate the potential of \[18F\]SynVesT-1 PET as an imaging biomarker for MSA
Spatial synaptic density alterations in MSA patients
时间窗: 10 months
To examine spatial synaptic density alterations in MSA patients
次要结局
未报告次要终点